DK1610796T3 - Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade - Google Patents

Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade

Info

Publication number
DK1610796T3
DK1610796T3 DK04757552.7T DK04757552T DK1610796T3 DK 1610796 T3 DK1610796 T3 DK 1610796T3 DK 04757552 T DK04757552 T DK 04757552T DK 1610796 T3 DK1610796 T3 DK 1610796T3
Authority
DK
Denmark
Prior art keywords
brain damage
impairment associated
neurological impairment
dopaminergic treatment
potency
Prior art date
Application number
DK04757552.7T
Other languages
English (en)
Inventor
Daniel E Katzman
Elkan R Gamzu
Neal M Farber
Esteban A Fridman
Marcelo Merello
Original Assignee
Neurohealing Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurohealing Pharmaceuticals Inc filed Critical Neurohealing Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1610796T3 publication Critical patent/DK1610796T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
DK04757552.7T 2003-03-17 2004-03-17 Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade DK1610796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45540503P 2003-03-17 2003-03-17
PCT/US2004/008120 WO2004082630A2 (en) 2003-03-17 2004-03-17 High potency dopaminergic treatment of neurological impairment associated with brain injury

Publications (1)

Publication Number Publication Date
DK1610796T3 true DK1610796T3 (da) 2014-07-21

Family

ID=33029995

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04757552.7T DK1610796T3 (da) 2003-03-17 2004-03-17 Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade

Country Status (7)

Country Link
US (1) US20070066996A1 (da)
EP (1) EP1610796B1 (da)
AU (1) AU2004222307B2 (da)
CA (1) CA2519117C (da)
DK (1) DK1610796T3 (da)
ES (1) ES2487415T3 (da)
WO (2) WO2004082630A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8308784B2 (en) * 2006-08-24 2012-11-13 Jackson Streeter Low level light therapy for enhancement of neurologic function of a patient affected by Parkinson's disease
US7534255B1 (en) 2003-01-24 2009-05-19 Photothera, Inc Low level light therapy for enhancement of neurologic function
US7303578B2 (en) * 2001-11-01 2007-12-04 Photothera, Inc. Device and method for providing phototherapy to the brain
US10315042B2 (en) * 2001-11-01 2019-06-11 Pthera LLC Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain
US20060058853A1 (en) * 2004-09-13 2006-03-16 Jonathan Bentwich Integrated system and method for treating disease using cognitive-training and brain stimulation and computerized magnetic photo-electric stimulator (cmpes)
US20070135859A1 (en) * 2005-12-09 2007-06-14 Peter Eriksson Use of transcranial magnetic stimulation to improve memory and stress related syndromes in humans
US7575589B2 (en) 2006-01-30 2009-08-18 Photothera, Inc. Light-emitting device and method for providing phototherapy to the brain
US20070179570A1 (en) * 2006-01-30 2007-08-02 Luis De Taboada Wearable device and method for providing phototherapy to the brain
CN101500559B (zh) * 2006-05-19 2014-01-08 海利空医疗公司 用于认知恢复和运动恢复的磷酸二酯酶4抑制剂
WO2009044271A2 (en) * 2007-10-04 2009-04-09 Neuronix Ltd. Systems and methods for treatment of medical conditions related to the central nervous system and for enhancing cognitive functions
WO2009044270A2 (en) * 2007-10-04 2009-04-09 Neuronix Ltd. Systems and methods for assessing and treating medical conditions related to the central nervous system and for enhancing cognitive functions
US7848035B2 (en) 2008-09-18 2010-12-07 Photothera, Inc. Single-use lens assembly
US10674943B2 (en) * 2012-09-07 2020-06-09 Medstar Health Research Institute, Inc. Method and system of rapid screening for mild traumatic brain injury (MTBI) and other cognitive impairment by analysis of intra-individual variability of motor performance
US20140336216A1 (en) * 2013-03-14 2014-11-13 Janssen Pharmaceutica Nv Physiological ligands for gpr139
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN111601587B (zh) 2018-01-18 2024-03-05 勒科斯生物技术责任有限公司 阿扑吗啡·棕榈酸共晶固体颗粒晶型
CA3138094A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
CN112933369B (zh) * 2021-01-27 2023-01-31 东南大学 一种脑卒中患者运动与感觉神经联合康复装置及控制方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2706767B1 (da) * 1993-06-22 1995-09-08 Lafon Labor
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US6463328B1 (en) * 1996-02-02 2002-10-08 Michael Sasha John Adaptive brain stimulation method and system
US5782790A (en) * 1996-05-31 1998-07-21 Allen; Cheryl L. Flexible compression and stabilizing orthotics
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
US6227203B1 (en) * 1998-02-12 2001-05-08 Medtronic, Inc. Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
IL155322A0 (en) * 2000-10-11 2003-11-23 Cephalon Inc Compositions comprising modafinil compounds
US6892098B2 (en) * 2001-04-26 2005-05-10 Biocontrol Medical Ltd. Nerve stimulation for treating spasticity, tremor, muscle weakness, and other motor disorders
US7297346B2 (en) * 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
FR2849029B1 (fr) * 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.

Also Published As

Publication number Publication date
EP1610796A4 (en) 2008-12-17
AU2004222307B2 (en) 2008-04-17
CA2519117C (en) 2010-03-02
WO2004082630A3 (en) 2004-12-29
AU2004222307A1 (en) 2004-09-30
WO2004082624A3 (en) 2004-12-02
WO2004082624A2 (en) 2004-09-30
US20070066996A1 (en) 2007-03-22
EP1610796A2 (en) 2006-01-04
ES2487415T3 (es) 2014-08-20
WO2004082630A2 (en) 2004-09-30
CA2519117A1 (en) 2004-09-30
EP1610796B1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
DK1610796T3 (da) Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1633726T3 (da) Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
AT507045A5 (de) Implantierbare, gewebe-stimulierende vorrichtung
EP1715799A4 (en) METHOD FOR TREATING GLAUCOMA
ZA200605950B (en) Treatment of ophthalmic conditions
DK1509121T3 (da) Okulærvisningsapparat til behandling af øjenlidelser
IS8530A (is) Meðferð á truflunum í auga þar með talinni sjóndepilsrýrnun
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
DK1694122T3 (da) N-arylhydrazonderivater til fröbehandling
DK1491212T3 (da) Middel til behandling af søvnforstyrrelser
DK1611111T3 (da) Fremgangsmåde til resolvering af 2,4-diamino-3,6-dihydro-1,3,5-triaziner der er egnede til behandling af lidelser som er forbundet med insulinresistenssyndrom
GB0409109D0 (en) Deep brain stimulation
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
NO20044092L (no) Oftalmisk sammensetning som innbefatter ascomycin
DE602004021069D1 (de) Nockenwellenverstellereinrichtung
IS8235A (is) 2-amínóbensóýl afleiður
GB2403908B (en) Artificial cornea
BR0312187B1 (pt) método para o tratamento de sementes
ES1057646Y (es) Protesis perfeccionada para el tratamiento quirurgico de las hernias de la ingle.
DE602005016584D1 (de) Hornhautbiometrie